Question · asked by 1 review
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo): Number of immediate (less than 24 hours) and delayed (24 hours to 10 days) postoperative bleeding episodes requiring intervention
- Population
- People with haemophilia (A or B) undergoing minor oral surgery or dental extractions
- Intervention
- Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid)
- Comparison
- Placebo, no intervention or usual care (with or without placebo)
- Outcome
- Number of immediate (less than 24 hours) and delayed (24 hours to 10 days) postoperative bleeding episodes requiring intervention
The review found no eligible studies for this question.
What each review found
Current versions onlyNo studies found 2 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo) Number of immediate (less than 24 hours) and delayed (24 hours to 10 days) postoperative bleeding episodes requiring intervention · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions · Immediate (<24 h) and delayed (24 h to 10 days) The review found no eligible studies for this question. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… (2019) · Cochrane All outcomes | This outcome was not reported in either of the trials. | 0 studies | No studies found |
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo) Number of immediate (less than 24 hours) and delayed (24 hours to 10 days) postoperative bleeding episodes requiring intervention · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions · Immediate (<24 h) and delayed (24 h to 10 days) The review found no eligible studies for this question. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… (2015) · Cochrane All outcomesearlier version CD011385.PUB2, superseded | This outcome was not reported in either of the trials. | 0 studies | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery… 2019 · Cochrane All outcomes | 2019-03 | Not listed | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo) · People of all ages on VKA or DOAC treatment undergoing oral or dental procedures… · 0 reviews
- Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo) · People with hemophilia (A or B) undergoing oral or dental procedures · 0 reviews
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.